SCHEDULE: Armistice Capital Reports 1.67% Stake in Travere Therapeutics

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 1,572,539 shares, representing 1.67% of the outstanding common stock of Travere Therapeutics, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Travere Therapeutics, Inc. common stock.
• The filing indicates that Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The total number of shares beneficially owned by the reporting persons is 1,572,539.
• This holding represents 1.67% of the class of securities.
• The Master Fund disclaims beneficial ownership of the securities it holds due to its investment management agreement with Armistice Capital.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without indicating a significant shift in strategy or performance.

Positives

• Reporting persons have disclosed their holdings, providing transparency to the market.
• The filing indicates a passive investment approach, with no stated intention to influence control.

Negatives

• The filing does not provide any information on the company's performance or strategic direction, only ownership details.
• The Master Fund disclaims beneficial ownership, which could indicate a complex ownership structure.

Risks

• While not explicitly stated as a risk in this filing, significant changes in beneficial ownership can sometimes precede activist campaigns or shifts in company strategy, though this filing suggests a passive role.
• The reliance on an investment management agreement for beneficial ownership claims could introduce complexities if the agreement terms change.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating stakes in publicly traded companies. Travere Therapeutics operates in the biotechnology sector, which often sees significant institutional investment and shifts in ownership.

Comparison to Industry Standards

• The 1.67% ownership stake reported by Armistice Capital is a relatively small percentage of the total class of securities, typical for an initial or moderate investment in a biotechnology company.
• Many institutional investors in the biotech sector hold stakes ranging from below 1% to over 10%, depending on their investment strategy and the company's stage of development.
• Competitors or similar-sized investors in the biotech space might hold similar or larger passive stakes, but specific comparisons require knowledge of other investors' filings.

Stakeholder Impact

• Shareholders gain transparency regarding a significant institutional investor's holdings.
• The market receives information about a 1.67% stake, which could be a minor factor in stock price movements depending on trading volume.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold their shares in Travere Therapeutics, Inc.
• Future amendments to this Schedule 13G will be filed if there are any changes in beneficial ownership as per SEC regulations.

Key Dates

Keywords

Travere Therapeutics, Schedule 13G, Beneficial Ownership, Armistice Capital, Investment Management, Common Stock, Ownership Stake